Figure 1.
Endometrial mRNA expressions variation in control, IF and RM patients.
Figure 1a: G-CSFR mRNA expression variation in control, IF and RM patients. Figure 1b: TYMP mRNA expression variation in control, IF and RM patients. Figure 1c: ITGB3 and PLAUR mRNA expressions variation in control, IF and RM patients. Figure 1d: CD40 mRNA expression variation in control, IF and RM patients. IF: Implantation Failures. RM: Repeated Miscarriages. Results expressed in concentration ratio (Arbitrary Units) between target gene mRNA level and reference gene mRNA level. (*) Statistically Significant Difference, p<0.05.
Figure 2.
Endometrial mRNA expressions variation after rhG-CSF stimulation.
Figure 2a: G-CSFR mRNA expression variation after rhG-CSF stimulation. Figure 2b: TYMP mRNA expression variation after G-CSF stimulation. Figure 2c: ITGB3 mRNA expression variation after G-CSF stimulation. Figure 2d: PLAUR mRNA expression variation after G-CSF stimulation. Anti G-CSF: 3 days culture with G-CSF blocking antibody daily supplementation at 3 µg/ml. G-CSF (1): 3 days culture with rhG-CSF daily supplementation at 20 ng/ml. G-CSF (2): 3 days culture with rhG-CSF daily supplementation at 100 ng/ml. G-CSF (3): 3 days culture with rhG-CSF daily supplementation at 200 ng/ml. Results expressed in concentration ratio (Arbitrary Units) between target gene mRNA level after culture with and without specific stimulation, each patient being her own control. (*) Statistically Significant Difference, p<0.05.
Table 1.
Correlation between target genes mRNA expression under G-CSF stimulation.